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Elevated plasma levels of the immunosuppressive complement fragment
Ba in renal failure. The complement fragment Ba is a 33 kD activation
product of factor B which suppresses human B-lymphocyte functions in
vitro. We report that plasma levels of Ba are highly elevated in patients
with chronic renal failure (4.84 3.58 gJml) and in patients with
end-stage renal disease undergoing regular hemodialysis (16.1 6.1
gIml) as compared to normals (1.01 0.30 tgIml). Ba levels were
strictly correlated with the creatinine clearance. The urinary excretion
of Ba was 165-fold higher in patients with tubular proteinuria than in
normals. These results indicate that the kidney is the major catabolic
site for Ba. In addition, direct evidence was obtained for an enhanced
turnover of the alternative pathway of complement in renal failure that,
although it appears to be less important than the renal retention of Ba,
contributes to elevated Ba plasma levels in these patients. Ba concen-
trations in dialysis patients who responded to hepatitis B vaccination
were significantly lower than in non-responders. Furthermore, the in
vitro 1gM synthesis by purified mononuclear cells was negatively
correlated with Ba concentrations determined in the plasma of these
patients. These results suggest that the accumulation of Ba contributes
to the defective immune response in patients with renal failure.
The involvement of complement in the pathogenesis of van-
ous renal diseases has been amply documented in the past.
Complement activation products such as C5a or the terminal
complement complex (TCC) are thought to contribute to the
local inflammatory response and to tissue injury found in
glomerulonephritides [1—3]. Adverse effects observed in a mi-
nority of patients undergoing hemodialysis with cuprophan
dialyzer membranes have been attributed to pro-inflammatory
complement activation products as well [4]. The finding of
immunomodulating properties of soluble complement compo-
nents in vitro in recent years has added a new and potentially
important biological function of this immunological effector
system [5—8]. As the immune system is known to be altered in
chronic renal disease resulting in an enhanced susceptibility to
infectious diseases [91, it was the aim of the present study to
quantitatively analyze complement fragments With immuno-
modulating properties in the plasma of patients with chronic
renal failure and with end-stage renal disease. Our findings
indicated that levels of the immunosuppressive complement
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fragment Ba were highly elevated in the patients studied. High
Ba plasma concentrations might contribute to the defective
immune response observed in patients with chronic renal dis-
ease.
Methods
Patients and controls
The study population consisted of 59 patients attending an
outpatient clinic for various chronic renal diseases and of 61
patients (28 male/33 female; mean age sD, 57.2 16.3 years)
with end-stage renal disease (ESRD) who were regularly under-
going hemodialysis. At the time of this study these patients had
been receiving dialysis treatment for 5.4 4.0 years (range 0.1
to 17.0 years). All patients were treated with cuprophan hollow
fiber dialyzers. Seven patients were dialyzed with E3S (Frese-
nius, Bad Homburg, Germany), 26 with URFO42 (Sartorius,
Gottingen, Germany) and 28 with GFS 12 (Gambro, Hechingen,
Germany). The diagnosis of chronic renal failure (CRF) was
assigned to 41 outpatients (22 male/19 female; mean age SD,
53.9 16.5 years) on the basis of creatinine clearance values <
80 mI/mm. The underlying causes of renal failure in these
patients (CRF/ESRD) were chronic glomerulonephritis (7
cases/12 cases); chronic pyelonephritis (4/13); diabetic nephrop-
athy (8/4); nephrosclerosis (7/3); polycystic kidney disease
(4/6); analgesic-associated nephropathy (2/6); interstitial ne-
phropathy (3/4); other or unknown causes were found in 6 CRF
patients and in 13 ESRD patients. All patients under study had
diagnoses that were documented by renal biopsy except for
those patients with polycystic kidney disease and with clinically
typical diabetic nephropathy. Normal volunteers (laboratory
personnel and healthy blood donors) served as controls (N =
55). Both serum and plasma containing 4 m dipotassium-
EDTA were obtained from all patients and controls. In ESRD
patients blood was drawn prior to hemodialysis. In addition,
EDTA blood was taken from 7 patients that underwent kidney
transplantation with an uneventfull postoperative course. Com-
plement proteins were also analyzed in urine samples from 13
healthy probands and from 10 patients with tubular proteinuna
and various underlying renal diseases. The presence of a
tubular type of proteinuna in these patients was documented by
microelectrophoresis and the densitometnc analysis of gels
which had been stained for protein with Coomassie Brilliant
Blue [10]. Freshly voided urine was mixed 9:1 (vollvol) with a
939
940 Oppermann et al: Ba in renal failure
100 mM Tris buffer, PH 8.4, containing 100 ifiM benzamidine,
100 mM epsilon-aminocaproic acid (EACA, Sigma, Taufkir-
chen, Germany), 200 mrvi EDTA (Serva, Heidelberg, Germa-
ny), and 10 sg/m1 of aprotinin (Boehringer Mannheim, Ger-
many) [11]. Ba, factor D and factor H were found to resist
degradation in proteinunc urine at pH ranges from pH 5.5 to pH
7.8 (37°C/24 hr) and were stable after the addition of inhibitors
at —70°C for at least 10 months. Total urinary protein was
determined according to Bradford [12] and creatinine by a picric
acid method (Beckman Instruments, Munich, Germany).
Quantitation of complement components
Complement components factor B, Ba, Bb, C3a, activated C3
(act C3), CSa, SC5b-9, factor D and factor H were quantitated
employing sensitive ELISA procedures developed in our labo-
ratory that are based on monoclonal antibodies. These assays
have been described in detail previously [13—161. The ELISA
for the quantitation of actC3 relies on a monoclonal antibody
with specificity for a neo-epitope that is expressed on activated
C3, that is, C3b, iC3b and C3dg, but is absent from native C3
[14]. Plasma concentrations of C3 were measured by rate
nephelometry using an ICS instrument and reagents provided
by Beckman Instruments.
Quantitation of 32-microglobulin and of immunoglobulins IgG
and 1gM
Determinations of -microg1obu1in were carried out by
ELISA employing reagents that were commercially available
(Dako, Hamburg, Germany) [17]. Hybridoma producing mouse
mAb with specificity for human IgG (HB 43) and human 1gM
(HB 57) were obtained from the American Type Culture Col-
lection (ATCC) and propagated as ascitic tumors in Balb/c
mice. Tandem ELISA procedures for the quantitation of human
IgG and of human 1gM, respectively, were established on the
basis of these mAb. Bound human immunoglobulins were
detected by the addition of biotinylated goat-anti-human Ig
preparations (Dianova, Hamburg, Germany) and streptavidin-
peroxidase (Amersham, Braunschweig, Germany).
In vitro complement activation by cobra venom factor
Normal human serum was depleted of factor D by gel
filtration n Sephadex G75 (Pharmacia, Freiburg, Germany)
[18]. D-depleted serum (50 d) was reconstituted with varying
amounts of purified factor D, and complement activation was
initiated by the addition of 10 pi cobra venom factor (CVF from
Naja naja kaouthia, Sigma; final concentration 10 pg/ml serum).
After incubation at 37°C for 15 minutes the reaction was
stopped by the addition of ice-cold EDTA (final concentration
20 mM). Sera of healthy controls (N = 11), CRF patients (N =
10), and of ESRD patients (N = 8) were treated using the same
protocol. The amount of Ba generated during the reaction
period was calculated from the Ba concentrations determined in
the CVF activated sera and the respective Ba levels in the
untreated controls.
Detection of complement components in urine by SDS-PAGE
and immunobiotting
The urine of a patient with cystinosis and tubular proteinuria
was analyzed by SDS-polyacrylamide gel electrophoresis (3 to
20% T) under non-reducing conditions and by immunoblotting.
Complement components C3dg, Ba, and factor D were isolated
from human serum as described [14] and were analyzed to-
gether with the urine samples. After electrotransfer to nitrocel-
lulose membranes, the complement proteins were visualized by
monoclonal antibodies with specificities for C3b/iC3b/C3dg,
factor B/Ba and factor D, respectively [14]. All mAb were
applied in biotinylated form and were detected by streptavidin-
peroxidase conjugates (Amersham, Braunschweig, Germany)
and 4-chloro-l-naphthol (Merck, Darmstadt, Germany).
Preparation of LPS-free Ba
The complement fragment Ba was prepared by the cleavage
of factor B by factor D in the presence of C3 and Mg + and was
subsequently purified to homogeneity by anion, exchange chro-
matography and gel filtration as described [14]. To eliminate
contaminating LPS from this preparation Ba was incubated (16
hr/4°C) with polymyxin B sepharose (Boehringer Mannheim) in
the presence of the dialyzable detergent octyl-f3-D-glucopyra-
noside (OBDG, Calbiochem, Frankfurt/Main, Germany; final
concentration 0.1 M) [19]. Finally, the sample was dialyzed
against pyrogen-free saline. After this procedure the Ba prepa-
ration contained < 10 pg LPS/ml as determined by a chromoge-
nic limulus amebocyte lysate assay (Kabivitrum, Munich, Ger-
many).
in vitro immuno globulin vynthesis by mononuclear cells
Mononuclear cells (MNC) were obtained from 15 healthy
controls, from 20 CRF patients and from 15 ESRD patients. At
the time of this study none of the patients received drugs known
to affect lymphocyte functions. Peripheral venous blood was
collected into EDTA (final concentration 4 mM) to prevent
complement activation. Blood was divided into a plasma frac-
tion for the analysis of complement activation products and a
cellular fraction for the separation of MNC. Pyrogen-free water
(Braun, Melsungen, Germany) was used to make up all buffers
that were used during cellular fractionation. Mononuclear cells
were prepared by density gradient centrifugation on Lym-
phoprep (Nyegaard, Oslo, Norway) [20], washed two times in
PBS and resuspended in Iscove's medium (Boehringer Mann-
heim) [21], supplemented with 2.5 mg/mI human serum albumin
(Behring), 10 g/ml transfemn and 10 ig/ml insulin (Sigma).
The purified cells were characterized by flow cytometry using
fluorochrome-labelled monoclonal antibodies and a FACStar
Plus flow cytometer (Becton Dickinson, Heidelberg, Germany).
Total T-lymphocytes were enumerated with a FITC-labelled
CD2-specific mAb (Dako), B-lymphocytes were quantitated
using CD19-FITC (Dako), natural killer cells were stained with
CD56-PE (NKH1-RD1, Coulter, Krefeld, Germany) and mono-
cytes were labelled with the CD14 mAb LeuM3-PE (Becton
Dickinson). Cultures were set up in 1 ml triplicates under
serum-free conditions in Iscove's medium at a density of 106
cells/ml, and were incubated in 24-well tissue culture plates
(Nunc, Roskilde, Denmark) either in the presence or the
absence of an optimal dilution (1/5000) of pokeweed mitogen
(PWM) (Gibco, Karisruhe, Germany). Cultures were kept for
seven days at 37°C, 5% CO2 in a humidified atmosphere, and
1gM and IgG concentrations were determined in the cell free
supernatants. Cells remained >85% viable after seven days of
in vitro culture as determined by Trypan blue exclusion. The
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Table 1. Complement components in patients with renal failure
Controls CRF ESRD
Protein Units N = 55 N 41 N = 61
Ba
.tg/ml 1.01 0.30 4.84 3.588 16.1 6.18
Bb g/m1 0.65 0.23 1.48 0.59a 1.57 0.768
actC3 g/ml 17.9 5.7 30.3 9.2a 30.6 1l.5
C3a ng/ml 32.1 19.3 30.0 15.4 33.8 13.9
C5a ng/ml 1.03 0.39 1.35 0.57 1.41 0.76
SC5b-9 ng/ml 213 82 183 108 167 71
C3 g/ml 1048 209 1288 388 1038 297
Factor B g/ml 238 48 272 84 218 70
Factor H g/ml 702 292 692 220 750 272
Factor D g/m1 1.05 0.27 4.35 3.038 12.1 353a
Creatinine mo1/1iter
/32-microglobulin g/ml
85 11
1.66 0.43
406 3278
9.43 8.38a
1034 2748
41.5 13.9a
8 p < 0.0001 compared with controls
same protocol was followed to study effects of purified Ba on
MNC cultures of healthy donors. Ba was present in the MNC
cultures throughout the seven-day incubation period. The max-
imal amount of LPS introduced by the addition of Ba was <0.5
pglml.
Hepatitis B vaccination protocol
Sixty-one ESRD patients were followed up for at least 27
months after the complement determinations were performed.
Thirty-three patients (14 male/19 female; mean age SD 58.2
15.0 years) with negative serologic markers of hepatitis B
infection were vaccinated with three 20 sg doses of hepatitis B
vaccine (H-B-Vax, Behring, Marburg, Germany). The vaccine
was given intramuscularly in the deltoid region at 0, 1, and 6
months. Six months after the last dose had been given, levels of
anti-HBs in vaccine recipients were determined by radioimmu-
noassay [22]. This assay detected all HBs-specific immunoglob-
ulins but did not permit differentiation between different Ig
subclasses. Nonresponders were defined as patients who had
anti-HBs levels of less than 10 mIU after three doses of
hepatitis B vaccine.
Statistical analysis
Values are given as mean 1 SD. Results were analyzed for
statistical significance by a unpaired Students's t-test. Correla-
tion coefficients were calculated by linear regression analysis. P
values <0.05 were regarded as significant.
Results
Plasma levels of complement components
The plasma levels of complement proteins determined in
patients with chronic renal failure or with end-stage renal
disease as compared to healthy controls are shown in Table 1.
The mean concentrations of factor D and of the complement
activation products Ba, Bb, and activated C3 in both the CRF
and the ESRD patients differed significantly (P < 0.001) from
normal levels. The mean Ba levels in patients with CRF were
almost fivefold higher and in ESRD patients more than 16-fold
higher than in the control group. Similar differences were
obtained for factor D, whereas elevations of activated C3 and of
the Bb fragment were much less pronounced. In contrast,
neither of the precursor proteins C3 or factor B, nor the
regulatory protein factor H or other complement activation
products were found to deviate significantly from the controls.
In 56 patients where the creatinine clearance had been
determined, a strict correlation between this parameter and the
respective Ba plasma level was established (Fig. 1). The corre-
lation between creatinine and Ba in the whole study population
(N = 120) was highly significant (r = 0.86; P < 0.001), but less
evident in the ESRD patients (r = 0.46) than in CRF patients (r
= 0.88). In ESRD patients a significant correlation (r = 0.52)
was observed between plasma concentrations of the Ba frag-
ment and factor B, which suggests that the synthetic rate of the
precursor protein factor B is an important determinant of Ba
plasma levels in these patients. Ba levels in the whole study
population were also positively correlated with 2-microglob-
ulin (r = 0.84) and with complement factor D (r = 0.81). Ba
plasma concentrations were not affected by the types of dialysis
membrane that were used in this study. The Ba levels in plasma
were found to be remarkably stable in 21 patients that were still
on hemodialysis after 28 months of follow-up. Overall, Ba
concentrations increased by 2.8% during this period and indi-
vidual values differed by 19.6%, on average, when Ba concen-
trations at the time of reevaluation were compared with the
initial values.
Ba and factor D in the plasma of renal transplant recipients
As shown in Figure 2 the elevated plasma levels of factor D
and of Ba in patients with end-stage renal disease returned to
normal levels within seven days after successful renal trans-
plantation. In patients where acute rejection episodes compli-
cated the postoperative course Ba and factor D plasma levels
virtually paralleled the serum creatinine values (not shown).
Urinary concentrations of the Ba fragment and of factor D in
patients with tubular proteinuria
Measurable quantities of factor D were detected in the urine
of 11 out of 13 healthy probands (0.62 0.33 nglml; Table 2).
The mean Ba concentrations in these 13 samples was 28.7
ng/ml. The urinary concentrations of Ba and of factor D in
patients with tubular proteinuna were elevated 165-fold and
370-fold, respectively, when these values were compared with
normals. These patients excreted 4.2 times more factor H (120
kD) in the urine than normals, but the Bb fragment could not be
detected in measurable amounts in normal nor in pathologic
urine. When these results were corrected for the higher total
protein contents of the patients' urine, concentrations of Ba
were significantly (P < 0.05) elevated in patients when com-
pared to normals. This result is in accord with the diagnosis of
a tubular type rather than of an unselective type of proteinuria
in these patients. To correct for differences in diuresis the
creatinine concentrations in the urine were determined as well
(Table 2). The structural identity of urinary Ba, factor D and
C3dg with the respective purified proteins was demonstrated by
SDS-PAGE of the urine of a patient with hereditary cystinosis
followed by immunoblotting with monoclonal antibodies (Fig.
3).
Factor D is the rate-limiting protease of the alternative
pathway of complement in vitro and in vivo
The amount of Ba generated in CVF-activated serum that had
been substituted with up to 10 pg purified factor D/ml was
Fig. 1. Correlation between plasma levels of Ba and
the serum creatinine (A) or the creatinine clearance
(B) in patients with chronic renal failure (0) and
with end-stage renal disease (a). The correlation
coefficients r were calculated by linear regression
analysis.
Time, days alter transplantation
Fig. 2. Plasma levels of Ba (0) and of factor D (0) in patients with
end-stage renal disease return to normal values within 7 days after
renal transplantation. Concentrations of the Ba fragment and of factor
D (mean SD) in the plasma of 7 patients with uneventfull postopera-
tive course are shown. Filled symbols represent normal values and
ranges of Ba and factor D.
strictly correlated with the respective factor D levels (Fig. 4).
Higher factor D concentrations than 10 g/ml did not lead to a
further increase in the in vitro Ba generation. Similarly, the
amount of Ba generated in CVF activated sera of 10 patients
with CRF (17.5 7.89 g BaJml) and of 10 patients with ESRD
(30.5 7.0 p.g Ba/mI) was significanily higher (P <0.001) than
in sera of 10 controls (4.7 1.4 pg Balml). Moreover, the Ba
levels generated in vitro were correlated with the factor D levels
determined in the respective sera.
Effects of Ba on the in vitro IgG and 1gM synthesis by MNC
LPS-depleted Ba dose-dependently inhibited the in vitro 1gM
synthesis by MNC (Fig. 5). Mononuclear cells had been iso-
lated from healthy blood donors and were cultivated for seven
days under serum free conditions. In contrast, the synthesis of
IgG was not affected by Ba. Furthermore, IgG or 1gM synthesis
FACS analysis revealed no significant differences in the
composition of MNC-subpopulations in the patients studied
with the exception of CDL9 positive B-lymphocytes that were
found depressed in ESRD (4.4 1.9%) and in CRF patients (6.9
2.8%) as compared to normal donors (8.6 7.7%). A
considerable interindividual variation in the in vitro immuno-
globulin synthesis in MNC cultures was observed (Table 3).
However, whereas no significant alterations in the IgG produc-
tion in patients compared to normals were observed, both the
spontaneous and the PWM-induced 1gM synthesis in ESRD
patients were significantly lower (P < 0.05) than in healthy
+ donors. The spontaneous 1gM synthesis was negatively corre-
lated (r = 0.37; P < 0.01) with Ba concentrations determined in
blood samples from which the MNC had been prepared (Fig. 6).
Immune response to hepatitis B vaccination
After three doses of hepatitis B vaccine only 9 out of 33
patients (27%) were considered anti-HBs positive. The mean
SD anti-HBs titer was 231 318 mIU/ml in the responders. Ba
plasma levels at the time of this study in the nine responders to
hepatitis B vaccination (12.6 4.8 pg/mt) were significantly (P
< 0.05) lower than in non-responders (16.4 5.2 tgIml). In
contrast, neither serum creatinine nor f32-microglobulin values
differed significantly in both groups (Table 4). Although there
was a tendency towards a lower age in the responder group
(52.6 18.4 years vs. 60.4 13.4 years in the non-responders)
this difference was not statistically significant. No other clinical
parameter related to responsiveness (including duration on
dialysis) was identified.
Discussion
Serum concentrations of low molecular weight proteins such
as /32-microglobulin, alpha1-microglobulin, light chains of im-
munoglobulin or the complement protein factor D are elevated
in renal failure [23—26]. These proteins are filtered at the
glomerulus and are subsequently reabsorbed and catabolized by
the proximal tubular epithelium. Factor D is an exceptional
complement protein in many respects. It is present in plasma as
an active enzyme and has both the lowest plasma concentration
by MNC was not influenced by (up to 100 jig/ml) Bb, the 60 kD
activation product of factor B (not shown).
In vitro immunoglobulin synthesis by patients' MNC
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and the lowest molecular weight of all native complement
components. In vivo nephron microperfusion and in vitro
perfusion of rat kidneys directly demonstrated that factor D is
almost completely absorbed and catabolized by the proximal
nephron after glomerular filtration [27]. In normal human sub-
jects factor D is rapidly eliminated via the kidney and neither
modified extrarenal catabolism nor changes in synthesis con-
tribute to elevated factor D levels observed in patients with
renal failure [28].
Alterations in chronic renal disease of biologically-active low
—30
Fig. 3. Characterization of complement proteins
C3dg, Ba, andfactor D in the urine of a patient
with tubular proteinuria. The purified proteins
were run in parallel to urine samples.
— 20 Complement components were separated on
SDS-PAGE (3 to 20% T) and visualized by
immunoblotting using mouse monoclonal
antibodies with specificities for C3dg. Ba and
factor D.
molecular weight complement fragments could not reliably be
detected until recently due to inadequate sensitivities and
specificities of available assays. We have therefore spent con-
siderable efforts to establish sensitive assays that are based on
monoclonal antibodies with specificities for activation-depen-
dent neo-epitopes on complement fragments [13—16]. Where
neo-epitope specific mAb were not yet available interfering
precursor proteins were specifically eliminated by mAb coupled
to paramagnetic particles rather than by precipitation steps.
These assays allowed to precisely quantitate the complement
Table 2. Concentrations of complement components Ba, Bb, factors D and H in normal (N = 13) and in proteinuric urine (N = 10)
Normals Patients with tubular proteinuria
ng/ml %" pgImg creatng/ml %" pg/mg creat
Ba
Bb
Factor D
Factor H
28.7
0.62
49.3
43.2
<10
0.33l
37.3
0.052 0.061
<0.02
0.001 0.001
0.085 0.055
1.6 1.7
<0.1
0.07 0.12
3.0 1.7
4754 63l3'
<10
230 313
205 237
1.023 1.272c
<0.02
0.291 0.692
0.041 0.033
128 l74C
<0.1
6.2 9.2
5.5 8.5
Abbreviation creat is creatinine.
a % of total urinary protein
b Factor D was not detectable in 2 out of 13 urine samples
P < 0.05 compared with normals
0
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Fig. 5. Purified Ba selectively inhibits 1gM (A), but not lgG ()
synthesis in mononuclear ce/Is, IgG and 1gM in the supernatants after 7
days of in vitro culture were determined by ELISA. The maximum
amount of endotoxin introduced in the cultures by the addition of Ba
was <0.5 pg LPS/ml. The data shown are the mean SD of a
representative experiment.
fragments C3a, C5a, Ba, Bb, and C3bIC3dg and the precursor
protein factor B as well as the regulatory proteins factor D and
factor H.
The main finding of this study was the detection of markedly
elevated levels of the Ba fragment in patients with chronic renal
failure (CRF) and with end-stage renal disease (ESRD). Ba
levels were strictly correlated with the creatinine clearance and
with the creatinine in serum in patients with CRF, regardless of
the underlying cause of renal failure. After successfull kidney
transplantation the Ba concentrations rapidly returned to nor-
mal values within seven days. Urinary excretion of Ba was
165-fold higher in patients with tubular proteinuna as compared
to normals. Similar results were obtained for factor D. These
Fig. 4. Factor D is the rate-limiting protease of the
alternative pathway of complement in vitro (A) and in
vivo (B). Symbols are: () controls; (0) CRF; ()
ESRD, A. The amount of Ba was quantitated in factor
D-depleted human serum that was reconstituted with
purified factor D (0 to 12 pg/mI) in the presence of
cobra venom factor (10 pg/mI; 15 minJ37°C). B. The
amount of Ba generated in serum after in vitro
activation with 10 pg CVF/ml (15 mini37°C) correlates
with factor D serum levels of the respective probands.
results are consistent with the interpretation that the kidney is
the major catabolic site for the 33 kD Ba fragment.
This study also confirmed earlier reports on elevated plasma
levels of the 24 kD protease factor D in patients with chronic
renal disease [25, 29]. None of the other native components of
the alternative pathway of complement (APC) analyzed in this
study were significantly different from normal values. As factor
D is the rate-limiting protease of the APC in serum [181, it was
tempting to speculate to which extent the enhanced activation
of the APC contributes to elevated Ba plasma levels in renal
failure. Pascual et al reported that either normal serum supple-
mented with purified factor D to tenfold its normal concentra-
tion or sera of ESRD patients more efficiently activated com-
plement via the APC than normal serum [301. However, the
authors stated that individual sera behaved unpredictably in the
different assays used, and discussed the possibility of hetero-
philic antibodies in patients' sera that in addition to factor D
might modify the response to different complement activators.
We similarly obtained conflicting results when we investigated
the Ba generation by zymosan in patients' sera with varying
factor D concentrations. Only when we employed cobra venom
factor, which activates complement solely via the alternative
pathway, significantly more Ba was generated in sera of pa-
tients with CRF or ESRD than in normal sera. Furthermore, the
amount of Ba generated under these experimental conditions
was directly correlated to the respective factor D serum con-
centrations. These results underline the enhanced capability of
patients with chronic renal disease to activate complement via
the alternative pathway.
To which extent the direct renal retention of Ba or the
enhanced activation of the APC contribute to elevated Ba
levels, respectively, cannot easily be deduced from the data
presented here. The two split products generated at equimolar
amounts during the activation of factor B are the fragments Ba
and Bb. The 60 kD Bb fragment may be regarded as a better
indicator of APC activation than Ba as impaired renal filtration
does not directly influence Bb levels. Whereas Bb is elevated
2.2-fold in CRF patients, plasma concentrations of Ba are
4.8-fold higher in CRF and 16-fold higher in ESRD patients
compared to normals. The impaired renal elimination of Ba
therefore seems to be the more important mechanism to deter-
mine Ba levels in renal failure. As the enhanced activation of
the APC is caused by the impaired elimination of the 24 kD
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Table 3. In vitro synthesis of IgG/IgM by purified MNC of healthy controIs (N = 15), CRF (N = 20) and ESRD patients (N = l5)
Without PWM PWM stimulated cells
Controls CRF ESRD Controls CRF ESRD
IgG ng/ml
1gM ng/ml
130 31
138 87
152 122
112 141
167 82
66 58"
917 545
1341 1289
689 649
870 1378
732 705
543 539"
a IgG and 1gM were quantitated in the supernatant of 106 purified MNC cultured for 7 days either in the absence or the presence of pokeweed
mitogen (P 1/5000).
b P < 0.05 compared with controls
Ba, i.tg/mI
Fig. 6. In vitro .cvnthesis of 1gM by isolated mononuclear cells of
healthy controls ('O) and of patients with CRF (0) andESRD (A). 106
MNC were cultivated for 7 days; results represent the mean of triplicate
determinations. The 1gM synthesis was correlated with Ba plasma
concentrations that were determined from the same blood samples from
which the MNC fractions were prepared.
protease factor D, the renal retention of low molecular weight
proteins may be regarded as the central underlying cause for
elevated Ba plasma levels in renal failure. It contributes both
directly (via impaired elimination) and indirectly (immunolog-
ically') to higher Ba levels.
The accelerated complement turnover in the patients under
study did not lead to a significant decrease in plasma concen-
trations of the precursor proteins factor B and C3. This finding
is explained by the wide ranges of normal values that obscure
minor deviations of complement protein concentrations. As
complement proteins are present in normal plasma predomi-
nantly in their native forms [98.8% (in moles) of total factor B]
moderate complement activation will be more easily detected
by changes in the concentration of activation products rather
than of the substrates. The demonstration of an enhanced
complement turnover in patients with renal failure was further
confirmed by the quantitation of activated C3, which comprises
C3b, iC3b and C3dg. In contrast, neither C3a nor C5a plasma
levels were found elevated in these patients. These findings are
in accord with a previous study on C5a generation in patients
undergoing hemodialysis, in whom we described normal C5a
levels in the predialysis period [31], but differ from a report by
Chenoweth, Cheung and Henderson, who described signifi-
cantly elevated CSa levels in hemodialyzed patients prior to
Protein Nonresponders Responders
Ba g/m!
actC3 pg/ml
Factor B g/ml
FactorDpp/ml
Creatinine p.mo!/liter
/32-microglobulin ig/ml
16.4 5.2
31.0 14.0
355 137
12.4±3.8
1016 181
39.0 10.9
12.6 4.8a
30.0 10.5
327 101
11.0±4.1
1088 277
44.2 17.1
a P < 0.05
hemodialysis [32]. We explain this discrepancy by the different
A assays used for the quantitation of C5a. Techniques that rely on
a precipitation step for the depletion of C5 tend to overestimate0 3 C5a levels in samples with low protein content [33], which is a
common finding in chronic renal disease. The assay used in this
study is based on a mAb with specificity for a neo-epitope on
C5a and, therefore, does not require the elimination of CS prior
to the test [15]. However, we cannot completely rule out the
possibility that both C3a and C5a are generated at higher levels
during APC activation in chronic renal failure, but escape
detection due to their rapid binding to cellular receptors [34,
35]. Reports on the downregulation of C5a receptors on neu-
trophils and monocytes from chronic hemodialysis patients
argue in favor of such a mechanism [36].
The renal retention of complement activation products and
the accelerated turnover of the alternative pathway of comple-
ment may have either beneficial or detrimental effects in pa-
tients with renal failure. It has been argued that elevated factor
D serum concentrations theoretically lead to enhanced C3b
deposition on microbial surfaces that activate complement and
may therefore facilitate their elimination [30]. Complement
activation products that were elevated in this study in renal
failure patients have recently been shown to be potent media-
tors of the immune response. Reports on the in vitro suppres-
sion of human B lymphocyte functions by the Ba fragment [81
are particularly interesting in this context, as the effects were
observed at Ba concentrations similar to those present in the
plasma of patients with CRF and ESRD. The results presented
in this paper have been obtained by employing isolated Ba that
had been thoroughly depleted of LPS. Low amounts of LPS
contaminating isolated complement fragments have been shown
to be critical in the interpretation of immunoregulatory func-
tions of these preparations [37]. In this study the Ba fragment
markedly reduced the in vitro 1gM synthesis of unstimulated
mononuclear cells from healthy donors. In contrast, the in vitro
IgG synthesis was not affected by LPS depleted Ba. These
Table 4. Complement components, creatinine and /32-microglobulin
in responders (N = 24) and nonresponders (N = 9) to hepatitis B
vaccination
0
400
0
300
00
.2'200 A0
A
0
100 00 0 A
A
A0 A 0 A A
0 5 10 15 20 25
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results suggest an isotype-specific effect on Ba on B lymphocyte
differentiation.
It has been argued that the physiological role of Ba is to
downregulate B lymphocyte functions when antibodies have
been produced by these cells in amounts sufficient to form
complement activating immune complexes [8]. What seems to
be a finely tuned interplay that helps to limit the immune
response after antigenic challenge under physiological condi-
tions may become unbalanced by the accumulation of Ba in
renal failure. The demonstration of a normal structure of Ba in
the urine of a patient with tubular proteinuria implies that
functionally active Ba is present in high concentrations in
patients with renal failure. The hypothesis that high Ba plasma
concentrations modify the immune response in renal failure was
tested by examining the in vitro IgG and 1gM synthesis of
unstimulated MNC that had been isolated from patients with
CRF and ESRD. The reduced in vitro immunoglobulin produc-
tion by purified MNC of patients with ESRD has already
previously been reported by others [38, 391. In addition, this
study shows that the decreased immunoglobulin formation is
mainly due to the impaired 1gM synthesis. Although the inter-
individual variation in the in vitro 1gM synthesis was obvious
markedly reduced values were particularly observed in those
patients with very high Ba concentrations in their blood. It is
presently not known at which stage of the differentiation or
activation the Ba fragment regulates B lymphocyte functions.
However, our data on the isotype-specific regulation of immu-
noglobulin synthesis imply a regulatory role for Ba in the
activation of immature B lymphocytes during the primary
immune response. The defect in B lymphocyte differentiation in
ESRD patients which is acquired under in vivo conditions may
thus still be detectable after prolonged in vitro cultivation in the
absence of the uremic milieu.
The hypothesis that high Ba plasma concentrations modify
the immune response in renal failure was further tested by
examining the in vivo immune response to hepatitis B vaccine
in ESRD patients. Only 27% of those patients in our study
population who were vaccinated were regarded as responders.
This poor response, which is lower than in other studies
[40—421, is in part explained by the higher age of our study
population. Ba levels in the nine patients who responded to the
vaccination were significantly lower than in 24 non-responders.
Other laboratory parameters that are altered in renal failure,
such as serum creatinine or f32-microglobulin, did not differ
significantly in either group. This is consistent with a previous
report that showed that the impaired response to hepatitis B
vaccination in renal failure is independent of the serum creati-
nine [43]. In this context it is important to notice that Ba plasma
concentrations in ESRD patients are not merely determined by
the residual kidney functions but are influenced by other
independent factors such as the synthesis of its precursor
protein factor B. The finding of stable Ba plasma concentrations
in individual patients during a 28-month observation period was
another essential prerequisite for these correlative studies.
Although Ba was thus the only parameter that was significantly
different between responders and non-responders, in our study
we did not assume that Ba is the only determinant that affects
the outcome of vaccination in dialysis patients. It has been
shown that the impaired immune response in uremia can, in
part, be attributed to the defective interleukin-2 production by
T lymphocytes. The simultaneous application of vaccine with
low doses of interleukin-2 induced protective anti-HBs titers in
a number of previous non-responders [44]. A definite answer to
the question, to what extent elevated Ba plasma concentrations
influence the immune response in uremia, will require further
studies on a larger series of vaccine recipients. Virtually no
function of the immune system studied so far remains unaf-
fected in uremic patients [9, 38, 39, 45]. Most of these defects
do not seem to be associated with alterations of the complement
system. However, the results reported here suggest that the
complement fragment Ba may be regarded as an immunosup-
pressive factor present in uremic serum that contributes to the
impaired immune response in renal failure.
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